The tesamorelin phase 3 program enrolled both men and women, and its FDA indication applies to both sexes. What it is approved for is narrow: excess abdominal fat in people with HIV, not age-related decline in the general population.
Tesamorelin is a GHRH analog with one FDA-approved use, and that indication applies to women as well as men. It is approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy [3]. The phase 3 trials that earned that approval enrolled both men and women [1]. Outside that specific population, tesamorelin is not approved, and women considering GH-axis therapy for age-related decline are usually looking at sermorelin instead.
- Tesamorelin is FDA-approved only for excess abdominal fat in HIV-associated lipodystrophy, in both sexes [3]
- The phase 3 program enrolled women, and pooled data showed visceral fat reduction over 26 weeks [1][2]
- It is not approved for age-related GH decline, menopause symptoms, or general weight loss
- For age-related decline, sermorelin is the more common telehealth option, and GHRH-analog trials included women [4]
- Pregnancy is a contraindication, and active malignancy is a contraindication on the tesamorelin label [3]
What Tesamorelin Is Approved For
Tesamorelin has a single FDA indication: reducing excess visceral and abdominal fat in adults with HIV who have lipodystrophy [3]. That indication is not sex-restricted. Women who meet it are candidates on the same terms as men. This is a targeted metabolic indication, not a general anti-aging or body-composition approval.
This distinction matters because tesamorelin is frequently discussed as if it were a general fat-loss peptide for women. It is not approved that way. Any use outside HIV-associated lipodystrophy is off-label, and the strongest evidence for tesamorelin sits inside that specific population.
What the Trials Showed, and Who Was In Them
The registration trials included women from the start. In the first phase 3 trial, tesamorelin at 2 mg daily reduced visceral adipose tissue over 26 weeks in HIV patients with excess abdominal fat [1]. A pooled analysis of two phase 3 trials with safety-extension data confirmed the visceral fat reduction and reported the safety profile across the combined population of men and women [2].
Two honest caveats belong here. The lipodystrophy population skewed male, so the female subgroups were smaller, and the benefit was driven by a metabolic problem specific to HIV therapy. That is a different starting point from a healthy woman in her 40s or 50s seeking body-composition change. The mechanism is shared. The evidence base is not the same population.
Tesamorelin's visceral fat data comes from HIV-associated lipodystrophy, a condition with a distinct fat-distribution problem [1][2]. It supports the mechanism. It does not, on its own, establish the same effect size in a woman without that condition.
Where Sermorelin Fits for Women
For age-related GH decline, sermorelin is the option most women actually encounter through telehealth. It is a GHRH analog that stimulates the pituitary to produce its own GH while somatostatin feedback keeps output self-limiting [5]. Like tesamorelin, it is compounded rather than FDA-approved for this use, so the honest framing is off-label peptide therapy, not an approved treatment.
The GHRH-analog evidence in women is not zero. In a controlled study of age-advanced adults, GHRH-analog dosing raised IGF-1 within 2 weeks and increased nocturnal GH in both men and women [4]. Body composition responses in that trial were more pronounced in men, which is a real limit worth stating rather than smoothing over.
| Tesamorelin | Sermorelin | |
|---|---|---|
| FDA status | Approved for HIV lipodystrophy only [3] | No approved product; compounded [5] |
| Typical use in women | On-label only for HIV lipodystrophy | Off-label, age-related GH decline |
| Strongest evidence | Visceral fat in HIV patients [1][2] | IGF-1 rise in age-advanced adults [4] |
| Dosing | 2 mg daily subcutaneous [3] | 100 to 300 mcg at bedtime |
| Cost | Brand-name, high | Compounded, lower |
Sermorelin and Hormone Therapy Are Different Axes
A common misunderstanding is treating sermorelin as an alternative to menopausal hormone therapy. They act on different systems. Estrogen and progesterone replacement addresses ovarian hormone decline. Sermorelin acts on the GH axis, a separate pathway that also declines with age. One does not substitute for the other.
In practice, a woman working with a hormone-focused clinic may be evaluated for both, because the symptoms overlap: disrupted sleep, changes in body composition, lower energy. The correct sequence is a baseline IGF-1 draw before any GH-axis therapy, interpreted against the age-adjusted range, so a decision rests on a real number rather than symptoms alone.
Contraindications That Matter for Women
- Pregnancy: tesamorelin is contraindicated in pregnancy on its label, and GH-axis therapy is not appropriate while pregnant or breastfeeding [3]
- Active malignancy: a contraindication on the tesamorelin label, since GH and IGF-1 signaling is a theoretical concern [3]
- Untreated hypothyroidism: correct it first, because it blunts the GH response
- No baseline IGF-1: prescribing GH-axis therapy without a baseline lab is a red flag regardless of sex
Bottom Line
Tesamorelin is a legitimate option for women who meet its one approved indication, HIV-associated lipodystrophy, and its trials included women [1][2]. For age-related GH decline, which is what most women are actually asking about, tesamorelin is off-label and sermorelin is the more common telehealth path. Neither substitutes for menopausal hormone therapy. Start with a baseline IGF-1, and work with a clinic that evaluates the GH axis on its own evidence rather than bundling it into a general anti-aging pitch.
For women weighing GH-axis therapy alongside hormone treatment, the setup that matters is real evaluation and a baseline draw, not a one-size protocol. Embody runs bioidentical hormone and sermorelin programs through a dedicated women's hormone team at $99/month.
Frequently Asked Questions
Is tesamorelin approved for women?
Yes, within its one indication. Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and that indication applies to both women and men [3]. The phase 3 trials enrolled women [1]. It is not approved for age-related decline, menopause, or general weight loss in women or men.
Can women take tesamorelin for weight loss?
Not as an approved use. Tesamorelin's only FDA indication is excess abdominal fat in HIV-associated lipodystrophy, a specific metabolic condition [3]. Its visceral fat data comes from that population [1][2], not from healthy women seeking weight loss. Any other use is off-label, and the evidence for it in that setting is limited.
Is tesamorelin or sermorelin better for women?
It depends on the reason for treatment. Tesamorelin is the right answer only for a woman who meets its approved HIV-lipodystrophy indication [3]. For age-related GH decline, sermorelin is the more common telehealth option, and GHRH-analog studies that included women showed IGF-1 rising within 2 weeks [4]. Both are off-label outside their respective evidence, so the choice belongs with a prescribing physician.
Does sermorelin help with menopause symptoms?
Sermorelin acts on the GH axis, not the ovarian hormones that decline in menopause, so it is not a substitute for hormone therapy. The symptoms can overlap, including disrupted sleep and body-composition changes, which is why some hormone clinics evaluate both. A baseline IGF-1 against the age-adjusted range should guide any GH-axis decision.
Is tesamorelin safe for women?
In the approved population, women were included in the safety data across the pooled phase 3 trials and extension [2]. The label lists contraindications that apply to women specifically, including pregnancy, and to both sexes, including active malignancy [3]. Outside HIV-associated lipodystrophy, long-term safety data in women is limited, so use is a physician-supervised, off-label decision.
Can you take sermorelin and hormone replacement together?
They target different systems, so a hormone-focused clinic may evaluate both. Hormone therapy addresses estrogen and progesterone decline; sermorelin addresses the GH axis. Neither replaces the other. The starting point is a baseline IGF-1 draw, and any combined plan should be managed by a prescribing physician who monitors both.
References
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- EGRIFTA SV (tesamorelin) for injection: full prescribing information DailyMed, U.S. National Library of Medicine, 2025. FDA-approved labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMC2699646. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
